AOS to face competition
Wednesday, 25 June, 2008
Advanced Ocular Systems (ASX: AOS) will have to contend with a new competitor for its Triesence injectable triamcinolone acetonide anti-inflammatory, company directors warned the market yesterday.
The new product, known as Trivaris, is manufactured by Allergan. The FDA recently approved the drug for sale.
It will be in direct competition with Triesence, which was developed by AOS and is sold under license through Alcon.
The potential effect on the company's royalties revenues is currently unclear, AOS said.
Injectable triamcinolone acetonide is mainly used to treat inflammation of the eyes and other similar ocular diseases and disorders.
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
TGA approves therapy for paediatric growth hormone deficiency
The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...
